An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: 'Bridging the gap between laboratory data and patient related outcomes'.

Our recommendation remains to offer and optimize hydroxycarbamide therapy and consider voxelotor in situations with severe anemia and related sequelae affecting the brain or kidney.